磺脲类

huánɡ niào lèi
  • sulfonylureas
磺脲类磺脲类
  1. 方法对47例联合使用磺脲类、双胍类而血糖控制不好的患者每天早餐前加服4mg罗格列酮钠,进行为期12周的临床观察。

    Methods A 12-week randomized , rosiglitazone sodium 4 mg / d added to 47 type 2 diabetes patients with poor glycemic control by sulfonylureas and metformin .

  2. 中药治疗2型糖尿病口服磺脲类降糖药继发性失效

    Clinical Observation on Secondary Inefficiency of Sulfonylureas Drugs for Diabetes Based on Spleen

  3. 应用诺和灵R治疗磺脲类药物继发失效2型糖尿病的临床观察

    Efficacy of Novolin R on type 2 diabetes mellitus patients with secondary failure to sulfonylurea

  4. 磺脲类继发失效糖尿病患者加用胰岛素疗效及胰岛B细胞功能变化

    Effect of treatment and change of islet function by adding insulin glargine on patients with second failure of sulfonylureas

  5. 格列本脲对糖尿病及正常大鼠心肌磺脲类药物受体mRNA的影响

    Effects of glibenclamide on mRNA level of ATP-sensitive potassium channels of heart in normal and streptozotocin induced diabetic rats

  6. 目的:调查糖尿病(DM)患者磺脲类药物受体基因16外显子-3T→C多态性与2型DM相关性。

    Objective : To explore relationship between sulfonylurea receptor gene polymorphism and type 2 diabetes mellitus in Chinese subjects .

  7. 目的:观察磺脲类药物继发失效的2型糖尿病应用诺和灵R的疗效。

    Objective : Studing the efficacy of the Novolin R in the treatment of type 2 diabetes mellitus patients with secondary failure to sulfonylurea .

  8. 目的探讨胰岛素联合用药治疗磺脲类(SU)继发性失效临床疗效。

    Objective To observe the clinical effect of combined use of insulin for secondary failure to sulfonylurea ( SU ) treatment .

  9. 目的探讨链脲佐菌素诱发的糖尿病模型大鼠的胰腺组织中自由基清除剂sodmRNA和磺脲类药物受体SURmRNA的表达,了解糖尿病时胰腺SOD和SUR的关系。

    Objective Probing into the expression of scavenger SOD and SUR 's mRNA in pancreatic tissue of diabetic rats induced by streptozocin to understand relationships between SOD and SUR .

  10. 观察益气养阴活血方药治疗继发性磺脲类失效的2型糖尿病(DM)患者的疗效,及对空腹血糖(FBG)、糖化血红蛋白(HbAlc)、C肽(CP)水平的影响。

    To observe the clinical efficacy of qi-yin-enriching and blood-activating herbs in the treatment of type 2 diabetes mellitus ( DM ) irresponsive to sulfaurea drugs , FBG , HbALc and C-P were measured .

  11. 目的研究2型糖尿病(DM)脂肪细胞胰岛素受体(ICIR)的改变以及胰岛素、肥胖、磺脲类药对其的影响。

    Objective To investigate the effect of insulin , obesity and sulfonylureas on adipocyte insulin receptor in type 2 diabetes mellitus ( DM ) .

  12. 目的:探讨2型糖尿病(T2DM)与磺脲类药物受体1(SUR1)基因多态性的关系。

    Objective : To study whether the polymorphism of human sulfonylurea receptor ( SUR 1 ) gene correlated with type 2 DM in Tianjin .

  13. 目的探讨缺血再灌注及缺血预适应(IPC)状态心肌磺脲类药物受体(SUR)亚型SUR2的分布及表达特征。

    Objective To investigate the characteristics of expression and regional distribution of sulfonylurea receptor subtype 2 ( SUR2 ) in the reperfusion and ischemic preconditioning ( IPC ) rat heart .

  14. 目的观察2型糖尿病(T2DM)患者在磺脲类继发失效(SFS)后改用格列美脲联合中效胰岛素(NPH)治疗的临床疗效。

    Objective It is to observe the clinical curative effect of Glimepiride and NPH on type 2 diabetic mellitus ( T2DM ) patients after the secondary failure of sulfonylurea ( SFS ) .

  15. 目的:探讨磺脲类药物受体(SUR1)不同基因型与体质量指数(BMI)、胰岛素抵抗之间的关系。

    Objective : This study was to investigate the relationship among allelic frequency of sulfonylurea receptor-1 gene ( SUR1 ), body mass index ( BMI ) and insulin resistance in gestational diabetes mellitus ( GDM ) .

  16. 方法:30例经磺脲类和α糖苷酶抑制剂治疗2个月以上的T2DM患者随机分为两组:①二甲双胍组:加用二甲双胍控制血糖;

    Method : Thirty patients with type 2 diabetes mellitus who were treated with sulphanylureas and acarbose at least 3 months were randomly divided into 2 groups : ① metformin therapy group : patients received metformin additionally to control blood glucose ;

  17. 采用动态血糖监测系统比较磺脲类药物治疗效果不佳的2型糖尿病患者睡前联合甘精胰岛素或中性鱼精蛋白锌胰岛素(NPH)治疗12周后血糖谱的变化。

    With the continuous glucose monitoring system , daily blood glucose profiles were compared in type 2 diabetic patients treated with glargine or neutral protamine hagedorn ( NPH ) at bedtime for 12 weeks . The blood glucose levels in these patients were previously not well controlled with sulfonylureas .

  18. 方法将磺脲类继发性失效2型糖尿病患者62例随机分为两组,治疗组32例,每日早餐及晚餐前皮下注射人胰岛素诺和灵50R及服吡格列酮15~30mg;

    Methods Sixty-two cases of type 2 diabetics with secondary failure to Sus were randomly divided into two groups . Thirty-two patients were in united treatment group : subcutaneously injected human-insulin Novolin 50R before breakfast and supper , and also taking orally pioglitazone 15-30 mg a day .

  19. 磺脲类药物对胰岛β细胞凋亡影响的研究进展

    Progress about the effects of sulfonylureas on islet β cells apoptosis

  20. 胰岛素强化治疗对磺脲类继发失效患者的疗效

    Intensive insulin therapy in patients with secondary failure of sulfonylurea efficacy

  21. 磺脲类药对心血管系统影响的研究进展

    The Research of Effects of Sulfonylurea Drugs on the Cardiovascular System

  22. 芬氟拉明对磺脲类失效的非胰岛素依赖型糖尿病的疗效

    Effect of fenfluramine on non-insulin dependent diabetes with sulfonylurea drug failure

  23. 胰岛素联合用药治疗磺脲类继发性失效临床观察

    Combination therapy with insulin for failure following sulfonylurea therapy in diabetes

  24. 自由基代谢和磺脲类药物受体关系的初步研究

    Preliminary study of association between metabolism of free radical and sulfonylurea receptor

  25. 人胰岛素在磺脲类药物继发失效中的疗效观察

    Clinical effect of Human insulin in secondary failure of sulfonylureas

  26. D组原磺脲类加睡前胰岛素组。

    Group D , sulfaurea drugs and bedtime insulin .

  27. 继发磺脲类药失效病理机制的探讨

    An investigation of pathogenesis related to secondary sulphonylurea failure

  28. 妊娠期糖尿病与磺脲类药物受体基因1多态性的相关性研究

    Study of the Association between Gestational Diabetes Mellitus and Sulfonylurea Receptor-1 Gene Polymorphism

  29. 属于磺脲类口服降糖药。

    Belongs to the class of medicines called sulfonylureas .

  30. 动态血糖仪监测继发性磺脲类失效血糖漂移的特点

    Continuous glucose monitoring in subjects with secondary sulfonylureas failure